Alnylam (ALNY) | Stock Overview & Key Data
Alnylam Performance Comparison
Stock Range
Today's Range
Low: $446.18
High: $461.53
on October 2, 2025
52 Week Range
Low: $205.87
High: $484.21
on April 9, 2025
on September 9, 2025
All-Time High: $484.21 on September 9, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$60.4B
EPS
-2.46
P/E Ratio (TTM)
-211.31
Forward P/E
-374.46
P/B Ratio
238.81
PEG Ratio
-0.72
Div. Yield
N/A
ROE
-257.83%
Beta
0.320
Debt to Equity
1,093.31
Financial Highlights
Profitability
Gross Margin
81.52%
Operating Margin
-2.09%
Profit Margin
-12.96%
Returns and Earnings
Return on Assets (TTM)
-2.63%
Return on Equity (TTM)
-257.83%
EBITDA
$-123.7M
Net Income (TTM)
$-319.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$19.04
Quarterly Revenue Growth (YoY)
17.30%
Quarterly Earnings Growth (YoY)
17.26%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Alnylam ALNY | 60.38B Large-cap | 2.54% | 3.13% | 39.79% | 72.77% | 97.32% | 72.02% | 135.43% | 213.60% |
| Vertex VRTX | 100.41B Large-cap | 7.07% | 1.96% | -10.54% | -15.44% | 0.76% | -10.20% | 38.49% | 51.45% |
| Regeneron REGN | 59.93B Large-cap | 8.01% | 3.82% | 9.54% | -4.09% | -16.11% | -40.76% | -16.94% | -0.34% |
| Insmed INSM | 29.94B Large-cap | 12.69% | 5.16% | 55.54% | 108.06% | 118.44% | 111.43% | 591.72% | 323.86% |
| Royalty Pharma plc RPRX | 21.04B Large-cap | 4.56% | 0.88% | 0.83% | 16.66% | 41.49% | 31.50% | -10.70% | -17.22% |
| Incyte INCY | 16.38B Large-cap | 5.66% | 0.35% | 26.57% | 38.42% | 24.09% | 27.84% | 26.10% | -9.88% |
Ownership & Short Interest
Insider Ownership
3.79%
Institutional Ownership
99.08%
Shares Short
4M
Short Ratio
3.28
Short % of Shares Outstanding
3.74%
Average 10-Day Volume
945K
Average 90-Day Volume
1M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ALNY's 52-week high and low?
- In the last 52 weeks, Alnylam reached a high of $484.21 (on September 9, 2025) and a low of $205.87 (on April 9, 2025).
- What is the market cap and P/E ratio for ALNY?
- Curious about Alnylam's size and valuation? Its market capitalization stands at 60.38B. When it comes to valuation, the P/E ratio (trailing twelve months) is -211.31, and the forward P/E (looking ahead) is -374.46.
- Does ALNY pay dividends? If so, what's the yield?
- As for dividends, Alnylam isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Alnylam's main competitors or similar companies to consider before investing?
When looking at Alnylam, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.41B Healthcare Biotechnology -10.20% 38.49% Regeneron
REGN59.93B Healthcare Biotechnology -40.76% -16.94% Insmed
INSM29.94B Healthcare Biotechnology 111.43% 591.72% Royalty Pharma plc
RPRX21.04B Healthcare Biotechnology 31.50% -10.70% Incyte
INCY16.38B Healthcare Biotechnology 27.84% 26.10% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alnylam Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Alnylam's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -257.83%, the Debt to Equity ratio from the most recent quarter is 1,093.31, and its Gross Profit Margin stands at 81.52%.
- What is the recent revenue and earnings growth for ALNY?
- Looking at Alnylam's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 17.30%, and quarterly earnings saw a YoY growth of 17.26%.
- How much of ALNY stock is held by insiders and institutions?
- Wondering who owns Alnylam stock? Company insiders (like executives and directors) hold about 3.79% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.08%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.